Search Results

Stay at the Forefront of GPCR Drug Discovery! Learn from pioneers shaping biased signaling, assay design, and pharmacology—skills you won't find it anywhere else. Stay at the Forefront of GPCR Drug Discovery Gain insider methods from the pioneers shaping biased signaling, assay design, and pharmacology—skills you won't find in any textbook or paper. ⧖ Hours of Expert Training ↓ Downloadable Resources ◕ New Courses added Quarterly Get Access to GPCR Courses Explore the Masterclasses Full classes require Premium. Filter by Category Filter by Level Filter by Instructor 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 ... 100 Learn directly from world leaders in GPCR research Access exclusive training from the scientists shaping the future of GPCR drug discovery Dr. Terry Kenakin Terry's Corner Author of 'A Pharmacology Primer', the definitive GPCR reference used by labs worldwide. Former GSK principal research investigator with 40+ years of industry experience. Dr. Sam Hoare Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies for assay design strategies. Pioneer in quantitative pharmacology methods. Dr. Yamina Berchiche Dr. GPCR Community builder for scientists with expertise in GPCR project strategy and translational applications. Unlock All GPCR Masterclasses – Save 95% Individual courses cost $300–600 each. With Premium, you get everything for just $249.99/year (less than $1/day). Hours of GPCR Masterclasses Downloadable Resources & Q&A Replays Weekly GPCR Insights (papers, jobs, events) Networking with a global scientist community One failed assay can cost $10,000+ in reagents and months of time. Think of Premium as insurance against wasted experiments and failed drug leads. 🔥 Upgrade to Premium Premium Yearly $249.99 $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. Access the Archive What Scientists Are Saying Dr. Hoare is very experienced in the field. What came as a pleasant surprise was how didactical and well-thought-out his course was—highly recommended. The really unexpected was that the Q&A sessions reached the highest level—beyond excellent. I am a convert! I will keep Dr. GPCR and the offered resources in my work sphere Anonymous Thank you for bringing this course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field Anonymous The content had enough depth to satisfy the hunger for theory while being full of practical knowledge Anonymous The best pharmacology teacher teaming up with the best GPCR community platform to help train and inspire the next generation of scientists. Also super-valuable for those of us learning how to teach pharmacology Anonymous Dr. Hoare's extensive and elaborative explanation of the topics at hand was excellent and very digestible. Thoroughly enjoyed learning from him Anonymous Dr. Kenakin is a leading expert in the field. Aside from his vast experience in drug development, not to mention his extensive publication record, Dr. Kenakin is a masterful teacher and communicator. Anonymous Frequently Asked Questions What is a GPCR Masterclass? A deep-dive training session led by top GPCR scientists, covering pharmacology, signaling, assays, and drug discovery. Each masterclass focuses on practical methods you can apply immediately to your research. Who should join? PhD students, postdocs, biotech/industry scientists, and anyone working with GPCRs who wants to accelerate their research and avoid common pitfalls that waste time and resources. How do I access the masterclasses? Premium members get unlimited, on-demand access to all masterclasses. Watch on any device, anytime. All content is available immediately after joining. Can I preview before joining? Yes – every course includes a free trailer that gives you a taste of the content and teaching style. How do I fit this in my schedule? Each masterclass is designed as a focused 60-90 minute session that you can watch in one sitting or break into smaller segments. Many members watch during lunch breaks or dedicate one evening per week to professional development. Why not just read books or articles on PubMed? Our experts share direct methods, shortcuts, and case studies not found in the literature. They reveal the "how" behind successful experiments that papers rarely explain, saving you months of trial and error. The GPCR Field Is Advancing Fast – Don't Fall Behind Stay ahead in drug discovery with insights from the world's top GPCR experts. Get Access Today!

Discover the Dr. GPCR Ecosystem, where we connect and empower the GPCR community in the United States. Home: About Accelerating GPCR Drug Discovery, Together Dr. GPCR is the global hub where academia meets industry, accelerating GPCR research, advancing drug discovery, and fostering a thriving community for collaboration. Join Free Today Go Premium Strategic Partners What did you miss from the Dr. GPCR Ecosystem? GPCR Courses Articles from the Ecosystem Beyond Clearance: The Strategic Power of Irreversible Drug Binding How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Understanding Enzyme Inhibition In GPCR Discovery Programs Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery GPCR Weekly News Dr. GPCR Podcast GPCR Flash News Our Vision Closing the gap between academia and industry to accelerate GPCR drug discovery. Home: Premium $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Select 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. Become a Premium member and be part of the vision

Whether you’re a scientist, student, or just curious, you’ll hear about discoveries, career stories, and the latest GPCR news. Jump in and get inspired! Strategic Partners Latest Podcast Episodes 2025-10-22 2025-08-19 2025-07-08 2025-09-22 2025-08-05 2025-06-11 2025-09-02 2025-07-22 2025-05-27 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... 20 Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player Listen and subscribe where you get your podcasts

Explore the world of GPCRs with Dr. GPCR Podcast! Join industry leaders as they share insights, stories, and groundbreaking discoveries, enriching our understanding of GPCRs. Delve into the science behind these vital components shaping our collective knowledge. Welcome to the Dr. GPCR Podcast Conversations with the world’s leading GPCR scientists. Exploring discoveries, careers, and ideas shaping human health. In each episode, we sit down with leading experts to explore their career journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology. Launched at the height of the pandemic, the Dr. GPCR Podcast was created with three goals: Share discoveries – Highlight the latest advances in the GPCR field. Amplify voices – Provide scientists a platform to showcase their work. Inspire the future – Motivate the next generation to pursue GPCR research. At its core, Dr. GPCR’s mission is simple yet ambitious: to bring the GPCR community together - across borders and disciplines - to connect, exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology. Latest Podcast Episodes More podcast episodes What others are saying about this podcast Really enjoyable science podcast! Dr. Yamina Berchiche interviews leading GPCR scientists on this vibrant, entertaining podcast. I really appreciate the way the podcast educates and mentors, particularly towards junior scientists but also to the community as a wholen Yamina is a great interviewer, getting insight and personal history from her guests. Am very grateful for Dr GPCR livening up the week in these difficult times! Sam @Pharmamechanic I think it's really well done. I'm genuinely interested to see how it evolves and grows over time, as I feel it has the potential to develop into something even more impactful. Anonymous This came at just the most perfect time. I hadn't heard a scientific talk outside my lab since February and was starved to hear someone else talk passionately about GPCRs. I've listened to the episodes multiple times and it's just like being at a conference getting new ideas. I just couldn't be happier y'all created this podcast. Anonymous Great initiative, thanks. Carrier paths, choosing research topics, switching fields, late start, failures and successes. Anonymous I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people. Anonymous Listen and subscribe where you get your podcasts

Explore the scientific conference program at DrGPCR for cutting-edge insights in GPCR research. Stay updated with our program today! Welcome to Flash News—your fastest track to the latest updates in GPCR research, pharmacology, and biotechnology. Stay informed with breaking news, announcements, and key industry trends—all published here before they appear on social media. 🚀 Want full access? Become Premium! Unlock exclusive resources like the University Vault, in-depth courses, and weekly insights that go beyond the headlines. 👉 Become Premium Strategic Partners Irreversible kinetics = strategic lever in drug design. October 27, 2025 Terry's Corner Read full article Receptor pharmacology has evolved. Irreversible interactions are no longer niche curiosities — they’re strategic levers that shape how molecules behave in vivo and whether candidates advance or stall in discovery. Inside Terry’s Corner, you’ll gain access to focused, high-impact modules built for teams who need to engineer binding kinetics, not just potency . These lessons bridge molecular pharmacology with real-world design strategy, giving discovery teams the tools to make smarter decisions earlier in the pipeline. Here’s what’s covered in this week’s lesson: Target depletion vs. replenishment dynamics — how offset rates control exposure windows, shape therapeutic durability, and influence dosing intervals. Structured tissue penetration challenges — why high-affinity molecules stall at the periphery and how to optimize kinetic profiles for deeper reach. Quantifying irreversible activity (K_inact / K_I) — turning persistent binding into measurable design parameters that guide candidate optimization. Join to learn the same principles guiding successful drug programs today. 🟢 Browse the full video vault and stay ahead of the curve: ✳️ Courses by Terry | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #Kinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDevelopment Persistent binding ≠ just covalent. October 24, 2025 Terry's Corner Read full article Why do some inhibitors act long after the drug itself is gone? It’s not always about covalent chemistry — often, it’s about kinetics. Irreversible interactions emerge when one simple imbalance tips the scale: inflow outpacing outflow. That’s why a compound like phenoxybenzamine can knock down receptor populations after just a brief exposure. And why slow-dissociating allosteric inhibitors can reshape signaling curves for hours — or even days — after dosing stops. When persistent binding meets structured tissues, this effect can amplify or collapse. High-affinity molecules can get trapped at the periphery of a tumor, never reaching the core. The result: inconsistent exposure, patchy activity, and sometimes, outright therapeutic failure. This isn’t a subtle nuance. Binding kinetics are a design variable, as critical as potency or clearance. Get it wrong, and the best molecule on paper stalls in development. Get it right, and you unlock durable efficacy with leaner dosing strategies. If your discovery strategy still treats kinetics as an afterthought, you’re already behind. ✳️ Read More: https://www.ecosystem.drgpcr.com/post/beyond-clearance-the-strategic-power-of-irreversible-drug-binding #GPCR #DrGPCR #Pharmacology #DrugDiscovery #BindingKinetics #ReceptorPharmacology #MedicinalChemistry #PKPD #DrugDesign Dr. GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs October 23, 2025 GPCR Weekly News Read full article This week’s Weekly News breaks down how to control target engagement—so duration, penetration, and PK/PD separation serve your program, not sink it. Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “irreversible” in real systems, anticipating PK/PD decoupling, and using k_inact/K_I when Ki falls short. 🔹 Podcast Spotlight: Dr. Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where AlphaFold still needs a chaperone). If you’re advancing covalent or tight-binding candidates—or building models meant to predict, not narrate —this edition is built to shorten cycles and reduce surprises. Read the full Weekly News ➤ https://bit.ly/3KVlL4m If it helps your team, share it forward. #DrGPCR #GPCR Irreversible Drugs – Trailer October 21, 2025 Terry's Corner Read full article Irreversible drugs change the rules of engagement. Unlike reversible ligands, their impact can persist long after the compound is gone — creating durable pharmacological effects that reshape how pharmacokinetics and pharmacodynamics intersect. In modern discovery programs, that’s a decisive advantage (or a hidden liability) in candidate selection. In this week’s lesson, you’ll unpack: Why low offset rates can mimic covalent effects without forming actual bonds. How target depletion and replenishment kinetics define the therapeutic window. How persistent binding alters structured tissue penetration — and why that matters for tumor targeting and beyond. These tactical frameworks are used to optimize molecules, sharpen PK/PD strategy, and mitigate downstream safety surprises before they appear in IND-enabling studies. Understanding irreversible interactions can mean the difference between a stalled program and a strategic breakthrough. Those who master kinetic pharmacology set the pace. 🟢 Join Terry’s Corner and sharpen your pharmacology toolkit. ✳️ Terry's Corner | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #DrugDiscovery #MedicinalChemistry #PKPD #ReceptorKinetics #DrugDevelopment October 16, 2025 GPCR Weekly News Read full article Enzymes decide which molecules get a real shot at efficacy. This week’s Weekly News is your practical guide to building enzyme inhibition into discovery—not as a checkbox, but as a strategy. We unpack inhibition modes (competitive, noncompetitive, mixed, uncompetitive), the messy truth of CYP450 allostery and DDIs, and why allosteric control can protect potency in substrate-rich environments. Plus: a mindset masterclass from Dr. Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process. And a tertiary read on ciliary micro-domains linking OPN3/MCR signaling to appetite and skin biology. Read the full Weekly News ➤ https://lnkd.in/eWkAphen If this helped, pass it along to a colleague who needs the signal. #DrGPCR #GPCR July 15, 2025 Dr. GPCR Podcast Read full article Stayed when others pivoted. Now leading the field. While others left GPCRs behind, Sokhom S. Pin stayed the course. From DuPont to Cerevel, he focused on GPCR biology and became one of the few deep experts still standing when the field surged back. Patience. Passion. Positioning. 🎧 Hear about the journey: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRdrugdiscovery #GPCR #GPCRtrainingprogram #DrGPCR July 14, 2025 Terry's Corner Read full article Pharmacology’s hidden power? The model behind the data 💡 Terry Kenakin shows how experimental snapshots can reveal much more—and how predictive frameworks guide modern drug discovery. 🟢 Built for pharmacologists building stronger pipelines and those rethinking legacy models. ✳️ https://www.terrykenakin.com #GPCR #DrGPCR #pharmacology #drugmodeling #terrykenakin July 14, 2025 GPCR Weekly News Read full article What drives Gq vs. Gs selectivity at PTH1R? This new Nature Chemical Biology paper reveals cryo-EM structures of Gq-bound PTH1R—highlighting how N-linked glycans and ICL2 interactions stabilize receptor conformations that favor Gq coupling. ♦️ Two distinct Gq-bound conformations ♦️ Comparison with Gs-bound PTH1R ♦️ Strategic implications for biased agonist design A critical advance for anyone working on class B1 GPCRs, bone biology, or biased signaling. ➡️ Read the paper: https://www.nature.com/articles/s41589-025-01957-6?utm_content=buffer3b1fa&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #DrGPCR #GPCR #PTH1R #BiasedAgonism #CryoEM #Pharmacology #Osteoporosis #DrugDiscovery July 12, 2025 Terry's Corner Read full article Linear, linkage, or probability? Dive into the logic of drug modeling with Terry Kenakin. In his latest lesson, he breaks down the essential models shaping modern pharmacology. Learn to “extend your eyes” and predict complex drug behaviors. 🟢 Browse the full catalog (and expect a new course every week!) ✳️ https://www.terrykenakin.com #pharmacology #drugmechanism #kenakin #GPCR #DrGPCR July 11, 2025 GPCR Weekly News Read full article Most GPCR teams aren’t failing because of bad science. They’re stalling because of slow decisions, misapplied models, and buried priorities. This week’s GPCR Weekly News helps you fix that. Terry’s Corner breaks down the 4 pharmacologic models that separate forecasting from guessing. Dr. Sokhom S. Pin shares how he built high-output, low-burnout teams—and earned his PhD while working full time. Yamina’s Corner exposes the silent drift killing GPCR programs (and how to reverse it). 💡Plus: New tools from Celtarys Research . Biotech strategy moves from Catalio Capital Management . And your voice in our survey. If your competitors are already applying these insights… can you afford to skip this week’s update? ✳️ Read the Weekly News → https://www.ecosystem.drgpcr.com/post/crush-data-confusion-conquer-gpcr-drug-discovery?utm_content=bufferd9b30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #GPCR #Pharmacology #DrugDiscovery #ScientificLeadership #DrGPCR July 10, 2025 Dr. GPCR Podcast Read full article Build the team you always wished you had. At Alkermes, Sokhom S. Pin didn’t just lead a lab. He built a culture. His team became known as “the happiest group in the company.” Why? Empowerment, trust, and zero tolerance for toxicity. It wasn’t luck. It was leadership. ✳️ Watch Ep. 169: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #biotechleadership #GPCRresearchcommunity #DrGPCR #teamculture July 10, 2025 Terry's Corner Read full article What if a single experimental snapshot could predict an entire in vivo drug profile in a range of organs? In Terry’s Corner latest lesson, discover how pharmacologic models do just that. From historical linkage theory to dynamic probability models, the comparison of data to theory will be discussed. 🟢 Read the full breakdown: ✳️ https://www.ecosystem.drgpcr.com/post/what-if-you-could-predict-drug-behavior-with-just-a-snapshot #GPCR #DrGPCR #pharmacology #DrugDiscovery #TerryKenakin #FoundationalScience July 8, 2025 Dr. GPCR Podcast Read full article Redefine what a PhD path can look like. Sokhom S. Pin didn’t quit his job, pause his career, or sacrifice family time. He built a PhD program inside BMS—while working full-time and raising three kids. Industry-based research. Employer-funded. Custom-built for impact. 🎧 Ep. 169 is available now: https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-169-with-dr-sokhom-pin #GPCRtraining #GPCRscientistnetwork #DrGPCR #nontraditionalPhD #GPCR #DrGPCR July 8, 2025 Terry's Corner Read full article The wait is over! Terry's Corner is LIVE! ✨ We've poured our passion for pharmacology into creating this essential resource, designed to meet you exactly where you are in your drug discovery journey. Dr. Terry Kenakin delivers razor-sharp insights, all on-demand. Ready to: Strengthen your pharmacology fundamentals? Bridge theory to practical drug development decisions? Push the boundaries with advanced concepts like allosteric modulation and residence time? Terry's Corner helps you make better decisions through better pharmacology. Enroll now: https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining #ScienceEducation #Pharma #GPCR #DrGPCR July 7, 2025 GPCR Weekly News Read full article How do chemokines and GPCRs decode selectivity? A landmark Cell paper delivers the answer—mapping how conserved and variable sequence–structure elements govern interaction logic across 46 chemokines and 23 GPCRs. The result: a framework for designing ligands with altered receptor preferences. ♦️ Defines “public” vs. “private” binding determinants ♦️ Highlights role of structured + unstructured regions ♦️ Includes a web tool + viral chemokine engineering demo This is a must-read for GPCR modelers, immunopharmacologists, and ligand engineers. ➡️ Read the paper: https://www.cell.com/cell/fulltext/S0092-8674(25)00398-8 #DrGPCR #GPCR #Chemokines #StructuralBiology #Pharmacology #ProteinEngineering #Immunology #DrugDiscovery July 4, 2025 GPCR Weekly News Read full article Stronger pharmacology drives smarter decisions in GPCR discovery. Terry’s Corner is now live —an on-demand learning hub led by Dr. Terry Kenakin . New and unique lessons are released weekly on Tuesday. Elevate your drug discovery program with 45+ lessons yearly. Whether you’re refining assay strategy or evaluating data, these lessons give you the tools to think clearer and act faster. Explore on-demand lessons by Dr. Terry Kenakin with short videos, clear summaries, and curated references. Also in this week’s Dr. GPCR Weekly: ♦️ Yamina’s Corner—GPCR consulting to de-risk and accelerate your pipeline ♦️ Celtarys’ validated TR-FRET assay for CB1/CB2 ♦️ Chemokine-GPCR selectivity decoded ♦️ PTH1R structures reveal Gq bias mechanisms ♦️ NMBR simulations uncover new activation pathways ♦️ Axcelead & Superluminal expand collaboration ♦️ Industry momentum: collaborations, new data, and next-gen GLP-1 strategies Unlock deeper insight—starting now. ➡️ Read the newsletter: https://www.ecosystem.drgpcr.com/post/pharmacology-at-your-fingertips-terry-s-corner-launches #DrGPCR #GPCR #DrugDiscovery #pharmacology #biotechnews #terrykenakin #GPCRconsulting July 2, 2025 Terry's Corner Read full article Terry's Corner is Officially LIVE! 🎉 This is your new go-to for mastering drug discovery pharmacology. No fluff, just clear, on-demand insights from Terry Kenakin. Building core expertise? Master dose-response, binding, kinetics, and foundational models. Driving drug discovery? Apply pharmacology to selectivity, ADME, and strategic decision-making. An experienced drug hunter? Sharpen your edge with allosteric bias, residence time, and translational PK/PD. Learn on-demand, apply immediately: https://terrykenakin.com #DrGPCR #GPCR #pharmacology #TerrysCorner #DrugDiscovery July 2, 2025 Celtarys - Media Partner Read full article Some biotech stories start in the lab. Celtarys began to with a thesis project, a new chemical strategy, and a vision to make fluorescence available for drug discovery. Now, they’re growing fast and partnering with Dr. GPCR to connect with the researchers who need them most. ✳️ Learn more about the partnership: https://www.ecosystem.drgpcr.com/celtarys-research-dr-gpcr-ecosystem #GPCRcommunity #ScienceCollaboration #FluorescentLigands #BiotechStartup June 30, 2025 Terry's Corner Read full article 10 GPCR pharmacology lessons. Zero fluff. Launching July 1, Terry’s Corner gives you the clarity and confidence to make better decisions—starting with: 🟢 The role of pharmacology in discovery strategy 🟢 Black & Leff’s operational model—finally made practical 🟢 Binding curves, orthosteric vs allosteric function, and real vs apparent affinity 🟢 Molecular dynamics and how they guide ligand design 🟢 Why Terry built this—and how it sharpens your next move 📅 Learn anytime. New course every week. 📬 Subscribe to The Kenakin Brief → https://www.terrykenakin.com #GPCRscience #drugdiscovery #TerrysCorner #GPCRpharmacology #ligandbindingv June 28, 2025 Terry's Corner Read full article Unlock your pharmacology potential with Terry’s Corner. No fluff. Just clear, on-demand insight from Dr. Terry Kenakin—built for scientists at every level. 🟢 Building core expertise? Learn dose-response, agonism, binding, bias, kinetics, and the models that build real confidence. 🟢 Driving drug discovery? Apply pharmacology to selectivity, ADME, early safety, and smarter decision-making. 🟢 Already a drug hunter? Sharpen your edge with allosteric modulation, residence time, molecular dynamics, and translational PK/PD. Learn on-demand. Apply immediately. Early access begins July 1 → https://www.terrykenakin.com #pharmacology #GPCRscience #drugdiscovery #TerrysCorner #biotechtraining 1 2 3 4 5 1 ... 1 2 3 4 5 6 ... 6 🔔 Don’t Just Stay Updated—Stay Ahead Flash News gives you a glance at what’s happening right now in the GPCR world. But to go deeper—with full presentations, expert courses, and exclusive resources—you’ll need more than just a headline. 🎓 Go Premium and unlock: 200+ expert presentations in the University Vault Weekly News with in-depth insights Exclusive courses and masterclasses 👉 Upgrade to Premium Today

Explore this week's edition of Weekly News, featuring expert insights on target engagement, a practical framework for irreversible drugs by Terry, and Dr. Jens Carlsson's take on predictive modeling. Gain valuable strategies to advance your covalent or tight-binding candidates and enhance your experimentation process. Read more for a premium sneak peek! Home → Flash News → Weekly News October 23 Dr. GPCR Weekly News - Oct 23 - The Power and Peril of Irreversible Drugs Published on October 23, 2025 Category GPCR Weekly News This week’s Weekly News breaks down how to control target engagement—so duration, penetration, and PK/PD separation serve your program, not sink it. Premium sneak peek inside. 🔹 Terry’s Corner: A practical framework for irreversible drugs—defining “irreversible” in real systems, anticipating PK/PD decoupling, and using k_inact/K_I when Ki falls short. 🔹 Podcast Spotlight: Dr. Jens Carlsson on predictive modeling—where structure-based design and MD guide experiments (and where AlphaFold still needs a chaperone). If you’re advancing covalent or tight-binding candidates—or building models meant to predict, not narrate —this edition is built to shorten cycles and reduce surprises. Read the full Weekly News ➤ https://bit.ly/3KVlL4m If it helps your team, share it forward. #DrGPCR #GPCR Recent Articles Previous Next

Stay up to date with the latest GPCR news and insights. Explore Dr. GPCR's classification and dive into the fascinating world of G protein-coupled receptors. Get GPCR news in your inbox every week —be the office genius! Sign Up Fresh Classified GPCR News Adhesion GPCRs Call for GPCR papers Contributors Articles GPCR Activation and Signaling GPCR Binders, Drugs, and more GPCR Events, Meetings, and Webinars GPCR Industry News GPCR Jobs GPCR Weekly News GPCRs in Cardiology, Endocrinology, and Taste GPCRs in Neuroscience GPCRs in Oncology and Immunology Methods & Updates in GPCR Research Reviews, GPCRs, and more Structural and molecular insights into GPCR function Sneak Peek! Content Exclusive for Premium Members* GPCR Weekly News October 2, 2025 Read More September 18, 2025 Read More September 17, 2025 Read More Contributors Articles Kiyan Afzali The Perils and Guardrails of Modifying Signalling Proteins in Bioassays Read More John Teye Azietaku Reflections on My PhD Journey: Lessons Learned Read More Cam Sinh Lu Harnessing Deep Mutational Scanning for Enhanced Drug Discovery Read More GPCR Industry News April 17, 2025 Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Read More April 14, 2025 Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron Read More April 22, 2025 Collaboration between Nostrum Biodiscovery and Celtarys Research: a strategic alliance Read More GPCR Events, Meetings, and Webinars GPCR Jobs Call for GPCR Papers Special Issue on Adhesion GPCRs Read More November 1, 2024 Emerging Voices in GPCR Biology in Special Issue of Molecular Pharmacology Read More September 27, 2023 opnMe GPCR Route 66+ project Read More Adhesion GPCRs March 25, 2025 Identification of a GPCR as a tip link-independent equilibrioceptor Read More March 26, 2025 Spatiotemporal profiling of adhesion G protein-coupled receptors in developing mouse and human pancreas reveals a role for GPR56 in islet development Read More February 18, 2025 A force-sensitive adhesion GPCR is required for equilibrioception Read More GPCR Activation and Signaling April 16, 2025 Insights Into the Cellular and Molecular Mechanisms Behind the Antifibrotic Effects of Nerandomilast Read More April 18, 2025 Challenging activity and signaling bias in tachykinin NK1 and NK2 receptors by truncated neuropeptides Read More April 16, 2025 Intercellular sphingolipid signaling mediates aversive learning in C. elegans Read More GPCR Binders, Drugs, and more April 1, 2025 Identification of anti-resorptive GPCRs by high-content imaging in human osteoclasts Read More April 7, 2025 Synthesis and Characterization of Photoswitchable Covalent Ligands for the β2-Adrenoceptor Read More April 4, 2025 Minimal Structural Variation of GPR84 Full Agonist Causes Functional Switch to Inverse Agonism Read More GPCRs in Cardiology, Endocrinology, and Taste April 8, 2025 The DNA repair factor ku80 binds and activates the adhesion receptor ELTD1/ADGRL4 Read More April 1, 2025 DRD2-Mediated AMPK Ubiquitination Regulates the Occurrence of Hepatic Steatosis Read More March 29, 2025 Genomic insights into ORs gene family of G protein-coupled receptors expansion driving omnivorous feeding in Spotted knifejaw (Oplegnathus punctatus) Read More GPCRs in Neuroscience March 31, 2025 Neurokinin 3 receptor agonist senktide stimulates GnRH release in isolated hypogonadotropic hypogonadism mice Read More April 1, 2025 Evidence for Bxy-npr-21 on controlling juveniles' growth and modulating male sexual arousal: from molecules to behaviors Read More April 1, 2025 Characterization of Anthozoan-Specific Opsins from a Reef-Building Coral, Acropora tenuis, as Gq-Coupled Opsins Read More GPCRs in Oncology and Immunology April 10, 2025 SIGMAR1 screened by a GPCR-related classifier regulates endoplasmic reticulum stress in bladder cancer Read More April 7, 2025 G-protein coupled receptors in metabolic reprogramming and cancer Read More April 4, 2025 Unveiling the Role of DPYS: A New Prognostic Biomarker in Sarcoma Read More Methods & Updates in GPCR Research April 18, 2025 Structural Systems Biology Toolkit (SSBtoolkit): From Molecular Structure to Subcellular Signaling Pathways Read More April 7, 2025 Topology-Driven Negative Sampling Enhances Generalizability in Protein-Protein Interaction Prediction Read More April 7, 2025 A new approach to psoriasis therapy: photoswitchable A3 adenosine receptor activation Read More Reviews, GPCRs, and more April 18, 2025 Discovery of Feeding Regulatory Peptides and The Importance of Peptide Discovery Research Read More April 9, 2025 Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics Read More April 1, 2025 Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail Read More Structural and molecular insights into GPCR function April 17, 2025 Structural dynamics of olfactory receptors: implications for odorant binding and activation mechanisms Read More April 15, 2025 Distinct activation mechanisms of CXCR4 and ACKR3 revealed by single-molecule analysis of their conformational landscapes Read More April 3, 2025 Proton perception and activation of a proton-sensing GPCR Read More UniversityPrice Choose your pricing plan Premium Yearly $ 249.99 249.99$ Every year 🚀 Everything you need to master GPCR science — in one membership. Select 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. Become Dr. GPCR Strategic Partner

Your go-to hub for everything GPCR! Stay ahead with the latest research breakthroughs, industry updates, job opportunities, and upcoming events—all in one place. GPCR Weekly News Your Hub for GPCR Research, Industry Updates, Jobs & Events Delivered straight to your inbox every week Become a Premium Member Welcome to GPCR Weekly News! Whether you're a GPCR scientist, biotech innovator, or industry professional, GPCR Weekly News keeps you connected to the discoveries and opportunities that matter most. Latest Research Breakthrough discoveries, new publications, and cutting-edge GPCR research insights. Industry Events Upcoming conferences, workshops, webinars, and networking events worldwide. Career Opportunities GPCR job listings, career tips, and networking opportunities in the field. Check Our Latest Issue Read the Free Edition Here's a preview of what you'll find in our latest newsletter Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma Dr. GPCR News 4 min read Get Premium for Full Access Latest Issue Enzyme Insight, Real-World Impact Oct 10 - 16, 2025 Read Full Issue Overcome Physiology. Accelerate Internalization. Elevate Discovery. Sep 19 - 25, 2025 Read Full Issue Design Assays That Tell the Truth Oct 3 - 9, 2025 Read Full Issue How Advanced Kinetics Prevents Discovery Blind Spots Sep 12 - 18, 2025 Read Full Issue Design GPCR Modulators with Intent: Orthosteric vs Allosteric Sep 26 - Oct 2, 2025 Read Full Issue De-Risk Discovery Decisions Early Sep 5 - 11, 2025 Read Full Issue 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 ... 7 About GPCR Weekly News GPCR Weekly News was launched in 2020 as part of the Dr. GPCR initiative. Our mission is to provide timely, relevant, and accessible information to scientists and industry professionals working in GPCR research and drug discovery. Every week, our team curates the most important developments so you never miss a breakthrough, opportunity, or event that could impact your work. Learn More about DrGPCR Best Value Premium Yearly $249.99 $ 249.99 Every year 🚀 Everything you need to master GPCR science — in one membership. Valid until canceled Join Premium Now 🎓 Full GPCR University + 🔬 200+ expert talks 🗞️ Weekly research, careers & event intelligence 🤝 Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠 Designed for researchers at every career stage 🚀 Don’t just keep up — lead the way. See all Discount Options Ready to Stay Ahead in GPCR Research? Join scientists worldwide who rely on GPCR Weekly News for the latest insights and opportunities. Become Premium Read our latest issue

Monitor GPCR internalization in real time with pHSense™ – no-wash, TR-FRET reagents from Revvity. Fast, clear, live-cell receptor trafficking detection. Unlock microscopy-free real-time GPCR internalization with pHSense pHSense™ probes are optimized reagents for plate readers, specifically designed to study internalization using time-resolved fluorescence (TRF) detection. They offer high-sensitivity, no-wash detection of internalization events in a scalable, plate-based format. This technology supports robust analysis even at low endogenous receptor expression levels. Suitable for basal/constitutive and agonist-induced GPCR internalization Compatible with TRF plate readers No-wash protocol simplifies workflow Formats available for modified GPCR cell lines or unmodified primary cells Explore pHSense Products Powered by Revvity’s legacy of innovation in translational science. Dr. GPCR Ecosystem Partner Visit Website Precision Tools for Translational Science Revvity is a global leader in life science innovation, delivering tools and technologies that bridge the gap between discovery and real-world impact. With decades of expertise and an unwavering focus on precision, Revvity empowers scientists to simplify complex workflows, accelerate discovery, and drive breakthroughs in drug development, diagnostics, and disease biology. Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity isn’t just a provider—they’re your partner in discovery. Discover pHSense™ portfolio From binding to signaling to internalization: Cell-based fluorescence assays for complete GPCR characterization The principle of pHSense™ relies on the pH-dependent fluorescence activation of a europium-labeled antibody to monitor receptor internalization in live cells. Neutral pH = low signal: The probe is minimally fluorescent at extracellular neutral pH (≥7), which means it doesn't emit a strong signal when bound to the surface. Internalization into acidic compartments = signal activation: Upon receptor-mediated endocytosis, the probe is internalized into acidic intracellular compartments (like early/late endosomes and lysosomes). The europium complex becomes increasingly fluorescent as the pH drops, enabling dynamic tracking of internalization. Time-Resolved Fluorescence (TRF) = High Signal-to-Background: Europium’s long-lived fluorescence allows TRF detection, which effectively filters out short-lived background signals. This results in high sensitivity and specificity in no-wash, plate-based live-cell assays. pHSense™ Eu Anti-FLAG Designed for the detection of FLAG-tagged receptor and membrane protein internalization. View Product pHSense Eu SNAP Labeling Reagent Can be used to label receptors and membrane proteins carrying an extracellular SNAP sequence with a pHSense probe to monitor their internalization View Product pHSense Fab Anti-Human or Anti-Mouse IgG Fab fragments for monitoring GPCR and antibody internalization in unmodified cells The Fab Anti-Human IgG Eu-conjugate can be used in combination with a neutral anti-GPCR to address unmodified receptors in primary cells View Product The Fab Anti-Mouse IgG2 Eu-conjugate is suited to study mouse biologics targeting GPCR and confirm their internalization effects on receptors. View Product The pHSense™ Advantage Clarity. Consistency. Compatibility. Purpose-Built for Live-Cell Internalization Assays The pHSense™ family of europium-labeled, pH-sensitive reagents is designed to simplify and accelerate the study of GPCR and membrane protein internalization in live cells. These reagents are fully compatible with plate-based, no-wash workflows and use time-resolved fluorescence (TRF) to eliminate background noise—delivering clear, quantifiable signals as targets move into acidic intracellular compartments. What Sets pHSense™ Apart ✅ Time-resolved detection minimizes background noise, which enhances detection sensitivity. ✅ No-wash protocol preserves cell integrity and kinetic detection. ✅ High-throughput ready: faster time-to-results and streamlined data acquisition. ✅ Comprehensive validation: validated for GPCRs, but also antibodies and ADCs. ✅ Versatility across suspension and adherent cells The Full GPCR Toolkit by Revvity Every step of the signaling cascade. One trusted source. GPCRs are among the most powerful and complex targets in biomedical research. Revvity offers a comprehensive reagent portfolio to match that complexity—supporting every stage of the signaling pathway, from ligand binding and G-protein activation to intracellular signaling readouts. With formats including TR-FRET, radioligand binding, cAMP, IP-One, and phospho-protein assays (ERK, AKT, CREB, MEK), this toolkit is built for speed, reproducibility, and translational insight. Proprietary no-wash technologies help reduce hands-on time while maintaining exceptional data quality—so you can move fast without compromise. View Reagents Explore Revvity’s GPCR Assay Technologies Tools designed to illuminate every step of GPCR signaling—from binding to downstream response. Ligand binding Measure receptor engagement with high sensitivity using TR-FRET, radioligand, and Fluorescent Tag-lite® formats. G-Protein Activation Quantify Gs, Gi, and Gq activation in real time with cAMP, GTP, and IP-One assays. Arrestin Recruitment Detect β-arrestin recruitment with TR-FRET and luminescence assays tailored for biased signaling studies. Intracellular Signaling Track key downstream events like ERK, AKT, and CREB phosphorylation with high-throughput precision. Build Your GPCR Assay Workflow Meet the Team behind pHSense™ Eric TRINQUET Sr Director Life Sciences Reagents, Revvity Eric Trinquet is a recognized expert in the field of immunoassays and fluorescence technologies. He currently leads Revvity's Research and Development activities, focusing on biochemical and cellular assay platforms related to Life Sciences Reagents. Before joining Revvity, Eric worked for Cisbio Bioassays first as Director of Technological Development and then as R&D Director. His career is marked by significant contributions, from introducing HTRF technology in the field of high-throughput screening to developing innovative solutions such as the IP-One kit for studying G Protein-Coupled Receptors (GPCRs) and the Tag-lite platform. Elodie DUPUIS R&D Senior project manager, team leader. Elodie Dupuis earned her Master’s degree in biology and biotechnology engineering from the University of Sciences of Nîmes and the Ecole des Mines engineering school (France) in 2009. She then joined Cisbio Bioassays, and later Revvity, as project leader and team manager in the Research & Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma, biotech, and academic partners. Through her research contributions, she has co-authored numerous scientific publications and holds several patents as an inventor. She has been leading collaborative projects with public research institutes and pharmaceutical companies, most notably the joint Revvity/Institute of Functional Genomics team, EIDOS. In 2020, together with her team, she initiated a long-term research effort that enabled the creation of a new and innovative portfolio for GPCRs, antibody drug conjugates, and several other applications: pHSense™. 2025 marked the commercial launch of the first pHSense products by Revvity. Mathis LAFFENETRE Product Manager, Immunoassay Reagents. Mathis holds a biotechnology engineering degree from the National School of Biomolecule Technology of Bordeaux and an MS in biomedical business management from the Grenoble School of Management. He joined Revvity (then Cisbio) in 2016 as part of the scientific marketing effort to build brand recognition for the HTRF technology and accelerate the company’s reagents use in academic labs, biotech companies, and pharma. In the following years, he held several marketing and strategic positions in France and the US, primarily related to the Immunoassay portfolio. As of 2025, he is part of the Immunoassay & Imaging Reagents Portfolio group as a product manager for the GPCRs, and is responsible for supporting the adoption and expansion of the reagent portfolio into the hands of scientists and researchers. Inside the Science: A Conversation with Revvity's Dr. Eric Trinquet From Rare Earth Probes to Internalization Assays: The pH Sense Story If you’ve ever used HTRF or wondered what goes into making a product worthy of your next experiment, this is your backstage pass. More about this conversation Our Partnership Dr. GPCR Spotlights Revvity’s pHSense™ Reagents for Real-Time GPCR Internalization A new reagent family designed to unlock high-throughput internalization workflows—now featured across the Dr. GPCR Ecosystem Boston, MA – September 2025 — Dr. GPCR, the global nonprofit platform dedicated to advancing GPCR research and drug discovery, is proud to spotlight the launch of pHSense™, a new reagent family from Revvity designed to bring unprecedented clarity, speed, and scalability to the study of receptor internalization. Internalization is a core—but often overlooked—dimension of GPCR biology. Traditionally, studying it has meant long workflows, low throughput, or expensive imaging platforms. pHSense™ changes that by combining europium-based, pH-sensitive probes with no-wash, live-cell protocols and TRF-based detection—making it possible to monitor internalization in real time, in standard plate-based assays. “When we saw dose-dependent internalization in endogenous GLP1R cells—without microscopy—that was the turning point,” said Dr. Eric Trinquet, Director of Research and Development at Revvity. “We knew pHSense could offer something truly new to the GPCR field.” A Tool Designed for Real Research Needs Built on more than two decades of GPCR assay innovation, pHSense™ was developed to overcome three persistent barriers in internalization studies: Complexity of imaging-based workflows Lack of scalability for high-throughput screening Difficulty detecting endogenous receptor activity With pHSense™, scientists can finally move beyond proxy readouts and track GPCR internalization as it happens—even at physiological expression levels. All four formats are validated in well-established models like GLP1R and Mu opioid receptor (MOR), and are compatible with HTRF plate readers already used in most labs. Related Articles How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. Dr. GPCR Podcast 6 days ago 4 min read The Truth About GPCR Product Launches: Years in the Making What it really takes to launch a GPCR product—years of failure, science, and strategy. Go behind the scenes of pH-Sense with Revity’s Dr. Eric Trinquet. Dr. GPCR Podcast Oct 8 4 min read Innovative Data-Driven Solutions: The pHSense Revolution A powerful new tool tracks GPCR internalization in native cells—no imaging, no overexpression. Learn how pH Sense changes the game for drug discovery. Dr. GPCR Podcast Sep 26 3 min read Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools Boston, MA – September 2025 — Dr. GPCR, the global nonprofit platform dedicated to advancing GPCR science through education, community, and platform visibility, is proud to spotlight pHSense™, a new reagent family from Revvity, now featured across the Dr. GPCR Ecosystem. Dr. GPCR News Sep 22 2 min read Dr. GPCR Ecosystem Partner Contact Revvity

Learn about Celtarys Research through the Dr. GPCR Ecosystem. Explore their innovative GPCR projects, collaborations, and contributions to cutting-edge drug discovery. Partnership Dr. GPCR x Celtarys Reseach Empowering medicinal biochemists Celtarys empowers medicinal biochemists by providing innovative fluorescent probes that de-risk the pre-clinical drug discovery phase. Our proprietary conjugation technology and unparalleled scientific expertise ensure researchers can confidently advance their projects with greater precision and reliability. Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools to spread the use of fluorescence-based methods in the pre-clinical phase of drug discovery. Our proprietary chemical conjugation technology allows us to grow, in a competitive manner and in a short time (<3 months), customized fluorescent ligands with optimal pharmacological and photophysical properties for any druggable target. We have a catalogue of over 30 fluorescent ligands for different families of GPCRs, including adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors. We also offer our expertise in the form of custom development services, where we tackle challenging targets and synthesize probes with the most suitable properties for your needs. Meet the Celtarys Team Wilson Gomes CEO Wilson Gomes holds a Mechanical Engineering degree, an MBA from the University of North Carolina, and completed the General Management Program at Harvard Business School. He has over 20 years of experience in the medtech and diagnostics industries, having held senior roles at Johnson & Johnson and Danaher across the EMEA region in sales, marketing, and general management. He joined Celtarys as CEO in 2024, where he is responsible for driving strategy and growth. His focus is on expanding commercial reach and accelerating the adoption of the company’s GPCR assay technologies. Maria Majellaro Co-Funder and CSO Dr. Maria Majellaro earned her degree in Pharmaceutical Chemistry and Technology from the University of Bari and completed her PhD in Biomolecular Sciences in Pharmacology and Medicine as “Doctor Europeus” in 2018. She then joined the University of Santiago de Compostela as a postdoctoral researcher in Prof. Eddy Sotelo’s group, contributing to the IGNICIA tech transfer project and the validation of Celtarys’ core technology. In 2021, she co-founded Celtarys and now leads the company’s scientific direction. Her work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma, biotech, and academic partners. Podcast Episode Baking Molecules, Building Probes: When Chemists Think Like Biologists Episode #168 • Dr. GPCR Talks with Dr. Maria Majellaro "We always start with the problem, then generate the right compound using our chemistry. It’s about enabling biology.” Celtarys News & Updates Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies Choosing the right fluorescent tools is important for the success of drug discovery, just as much as choosing the right targets. One of the best tools to study therapeutic targets are fluorescent ligands, which are very useful in GPCR drug discovery, starting from hit and lead validation all the way to pre-clinical assays. Some of the advantages of using fluorescent ligands for this are Lucía from Celtarys Research Sep 23 4 min read Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research What is Homogeneous Time-Resolved Fluorescence (HTRF)? HTRF is a hybrid detection technology that combines Förster Resonance Energy... Lucía from Celtarys Research Sep 17 4 min read 1 2 3 4 5 Our Partnership Dr. GPCR and Celtarys Research Join Forces to Expand Access to Innovative GPCR Tools Boston, MA and Santiago de Compostela, Spain — June 3rd, 2025 — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,” said Dr. Yamina Berchiche, Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,” said Wilson Gomes, CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,” added Dr. Maria Majellaro, CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit https://www.ecosystem.drgpcr.com/celtarys-research Services & Expertise Fluorescent Probes Innovative fluorescent probes that de-risk the pre-clinical drug discovery phase with optimal pharmacological properties. Custom Development Customized fluorescent ligands developed in less than 3 months with optimal properties for any druggable target. GPCR Expertise Specialized knowledge in adenosine, dopamine, serotonin, cannabinoid and muscarinic receptors for advanced research. Product Catalog GPCR Ligands Our GPCR fluorescent ligands are the ideal solution for your High Throughput Screening (HTS) needs. GPCR Functional Assay Fluorescent GTPγS enables sensitive, non-radioactive GPCR activity assays for drug discovery. Custom Development Tailored fluorescent probes designed for unique research requirements. Contact Celtarys Research First name* Last name Email* Write a message Submit Get in Touch Address Avda. Mestre Mateo 2, Santiago de Compostela, 15706, Spain Email Website LinkedIn

Expert support, trusted CROs, and ready-to-use tools to accelerate GPCR drug discovery, reduce risk, and advance your discovery-stage projects. Dr. GPCR Foundry: Accelerate GPCR Drug Discovery Expert guidance, CRO partnerships, and proven tools to reduce risk and move faster in GPCR drug discovery. 👉 Book a Free 30-min Strategy Call Why Biotechs choose Dr. GPCR Foundry? The Foundry is built for GPCR biotech companies at the discovery stage . 🔬 Validate your first target with confidence ⏱️ Scale programs faster with proven timelines 🤝 Access credible GPCR CROs and expert consultants 📚 Train and upskill your team with specialized programs 📢 Gain visibility through trusted media partnerships We connect you to: Specialist consultants Trusted GPCR CROs Proven timelines Upskilling resources Media opportunities for visibility Who is the Foundry for? GPCR biotech companies working on discovery-stage programs who need guidance, support, or specialist partners — wherever you are in your journey, we meet you where you are. You need Foundry if you're: ✔ A GPCR biotech startup validating your first target ✔ An established biotech looking to scale ✔ See king credible GPCR CROs for discovery-stage work Explore Resources for GPCR Biotech Companies 📊 Expert Guidance Struggling to plan your next discovery project? Get clarity fast. Avoid costly missteps with expert-backed strategies. Gain confidence with a roadmap tailored to your biotech goals. → Yamina’s Corner 👉 Book a Consulting Call with Yamina 📚 Specialized Training Your team lacks deep GPCR expertise? We close the gap. Learn proven methods that accelerate discovery outcomes. Stay competitive with structured, science-driven upskilling. → Dr. GPCR University 👉 Explore Training Programs 🧪 Science Into Practice Overwhelmed by complex GPCR data? Simplify it. Translate cutting-edge science into actionable steps. Turn research into real discovery progress. → Terry's Corner 👉 Join the Pharmacology Course 📢 Visibility & Reputation Hard to stand out in a crowded field? Get noticed. Build trust by showcasing your expertise worldwide. Connect with biotech innovators looking for CROs and partners. → Dr. GPCR Media Partner 👉 Become a Media Partner 🔑 On-Demand Knowledge Missing critical insights from past events? Access them anytime. Avoid wasting hours searching for answers—find them instantly. Revisit breakthrough presentations when your team needs them most. → Dr. GPCR University Vault 👉 Access the Vault 👥 Team Advantage Your team learning in silos? Align everyone with one hub. Equip staff with the same cutting-edge GPCR resources. Build collective expertise to accelerate discovery together. → Dr. GPCR University Team Membership 👉 Upgrade Your Team 🚀 Biotech Growth Workshops Still guessing how to scale your biotech? Stop. Eliminate trial-and-error with structured growth frameworks. Learn to scale with confidence—without wasting time or capital. → Timeline Strategy 👉 Build Your Biotech Strategy Help your GPCR discovery program succeed Discovery Consulting & Strategy Trusted guidance to reduce risk and improve project planning. Visibility for GPCR CROs Media partner packages that connect CROs with biotech innovators. Training & Upskilling Specialized courses designed for discovery-phase GPCR programs. Tools & Templates Practical, ready-to-use resources tailored to discovery-stage GPCR work. ✉ Contact Us Our Partners Join these innovative organizations already benefiting from the DrGPCR Foundry. Current Partners Book Book a 30-minute Strategy Call with Yamina. Let's move your GPCR discovery program forward. Wherever you are in your discovery journey, the Foundry helps GPCR biotech companies move faster and reduce risk. Let's discuss your next step.

Can models predict drug outcomes? Jens Carlsson shares how GPCR modeling is moving from explanation to real prediction in drug discovery. Strategic Partners Dr. GPCR Podcast << Back to podcast list Model. Predict. Discover. with Dr. Jens Carlsson What if models didn’t just explain the past — but could truly predict what comes next? In this episode, Dr. Jens Carlsson reveals how computational modeling is evolving from explanation to real prediction—and how that shift accelerates real-world discovery. Dr. Jens Carlsson, Professor of Computational Biochemistry at Uppsala University, joins Dr. Yamina Berchiche to share his unconventional journey from aspiring engineer to GPCR modeler. With a deep focus on structure-based drug design, Jens discusses how his lab bridges simulation and experiment—and why understanding the limits of prediction is just as critical as the predictions themselves. From virtual screening of billions of molecules to leveraging AlphaFold for structure prediction, Jens shares the cutting-edge tools his lab uses—and the collaborative mindset required to turn models into testable hypotheses. Along the way, he reflects on key career moments, the role of mentorship, and how curiosity continues to drive his work across both academic and industry settings. Why This Matters Computational models are moving beyond interpretation into real-world prediction of ligand-receptor interactions. Bridging computation, chemistry, and pharmacology is key to speeding up drug discovery. AI and machine learning are opening new doors—but only if scientists know their tools’ limits. What You’ll Learn Why Jens Carlsson believes modeling should predict , not just explain How his team uses structure-based modeling to identify novel GPCR ligands The value of failure—and how it shaped his path as a scientist Why collaborations between modelers and experimentalists are more vital than ever How AlphaFold is shaking up structural biology—and where it still falls short Advice for junior scientists: what really matters when building a research career Who Should Listen GPCR scientists and pharmacologists Computational chemists and structural biologists Early-career researchers exploring drug discovery Biotech leaders and R&D strategists Anyone interested in predictive modeling, AI in biology, or structure-function relationships About Jens Carlsson Jens Carlsson is a Professor of Computational Biochemistry at Uppsala University, where his research group uses structure-based modeling to investigate GPCRs. His team focuses on understanding how ligands modulate receptor function and how those insights can drive drug discovery. By combining molecular docking, molecular dynamics, and machine learning, Jens works at the intersection of computation and pharmacology, often in close collaboration with experimental labs. Trained initially as a biotechnology engineer, Jens discovered his true calling during an internship where his modeling skills stood out, mainly because his bench skills didn’t. That moment launched a career built around using computational tools to answer big biological questions. His journey took him from Sweden to Scripps Research and UCSF, where he was first introduced to GPCRs and mentored by pioneers like Brian Shoichet and Ken Jacobson. Jens is passionate about prediction over explanation: building models that can guide experiments, not just interpret them. Outside academia, he advises companies through a consulting arm focused on ligand design strategy. With a reputation for collaborative science, Jens is a strong advocate for bringing together chemists, modelers, and biologists to accelerate discovery and train the next generation of GPCR researchers. Jens Carlsson on the web Carlsson Group Uppsala University LinkedIn Hit play now to hear how prediction is reshaping GPCR science, and what that means for the future of drug discovery. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs The Truth About GPCR Product Launches: Years in the Making Innovative Data-Driven Solutions: The pHSense Revolution Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → In case you haven’t heard, Dr. Terry Kenakin will soon start the course Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection 📖 The five-lecture series describes essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic opportunity. Published on October 22, 2024 Category Dr. GPCR Courses In case you haven’t heard, Dr. Terry Kenakin will soon start the course Principles of Pharmacology II - Advanced Methods for the Optimization of Candidate Selection 📖 The five-lecture series describes essential additional elements to GPCR discovery programs that extend the discovery process and increase therapeutic opportunity. ✳️ Register today! https://www.ecosystem.drgpcr.com/advanced-methods-for-the-optimization-of-candidate-selection #gpcr #drgpcr Recent Articles Previous Next

Home → Flash News → What do GPCRs, acidic endosomes, and cancer immunotherapy have in common? Find out in our latest episode featuring Ian Chronis, where we explore the surprising ways GPR65 signals in different environments! ✅ Tune in: https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast Published on April 15, 2025 Category Dr. GPCR Podcast What do GPCRs, acidic endosomes, and cancer immunotherapy have in common? Find out in our latest episode featuring Ian Chronis, where we explore the surprising ways GPR65 signals in different environments! ✅ Tune in: https://buff.ly/FTB69y9 #GPCR #DrGPCR #SciencePodcast Recent Articles Previous Next

Home → Flash News → 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on April 29, 2025 Category Dr. GPCR Podcast 🚀 Science and finance aren't opposites—they’re partners. In this Ep.165 of the Dr.GPCR Podcast, Joe St. Germain & Chuck DeWeese reveal what it really takes to build sustainable startups and nonprofits behind the scenes. Grant accounting, character-first hiring, mission-driven growth—it’s all here! 🎧 Listen now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Recent Articles Previous Next

Home → Flash News → ⚠️Registration Deadline today! This is your last chance to register for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin. Learn theoretical background for the techniques and apply with hands-on exercises 💪 ✳️Last chance!!! https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 14, 2025 Category Dr. GPCR Courses ⚠️ Registration Deadline today! This is your last chance to register for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin. Learn theoretical background for the techniques and apply with hands-on exercises 💪 ✳️ Last chance!!! https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Recent Articles Previous Next

Home → Flash News → Did you know that cell types can affect the GPCR-mediated signalling cascade? Check out this paper to know how different cell types affect the A2BR-mediated calcium signalling system. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr Published on January 14, 2025 Category GPCR Weekly News Did you know that cell types can affect the GPCR-mediated signalling cascade? Check out this paper to know how different cell types affect the A2BR-mediated calcium signalling system. Check out the latest GPCR news in the Ecosystem today! You’ll need to register but don’t worry, it’s Free! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a2b-adenosine-receptor-triggered-intracellular-calcium-mobilization%3A-cell-type-dependent-involvement-of-gi%2C-gq%2C-gs-proteins-and-protein-kinase-c #gpcr #drgpcr Recent Articles Previous Next

Home → Flash News → encoding and decoding selectivity and promiscuity in the human chemokine GPCR interaction network Published on July 7, 2025 Category GPCR Weekly News How do chemokines and GPCRs decode selectivity? A landmark Cell paper delivers the answer—mapping how conserved and variable sequence–structure elements govern interaction logic across 46 chemokines and 23 GPCRs. The result: a framework for designing ligands with altered receptor preferences. ♦️ Defines “public” vs. “private” binding determinants ♦️ Highlights role of structured + unstructured regions ♦️ Includes a web tool + viral chemokine engineering demo This is a must-read for GPCR modelers, immunopharmacologists, and ligand engineers. ➡️ Read the paper: https://www.cell.com/cell/fulltext/S0092-8674(25)00398-8 #DrGPCR #GPCR #Chemokines #StructuralBiology #Pharmacology #ProteinEngineering #Immunology #DrugDiscovery Recent Articles Previous Next

Home → Flash News → The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 17, 2025 Category Dr. GPCR Courses The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Recent Articles Previous Next

Discover how enzyme inhibition can enhance drug discovery strategies. Explore inhibition modes, CYP450 allostery, and insights from Dr. Eric Trinquet in this week's news. Home → Flash News → Weekly News October 16 Published on October 16, 2025 Category GPCR Weekly News Enzymes decide which molecules get a real shot at efficacy. This week’s Weekly News is your practical guide to building enzyme inhibition into discovery—not as a checkbox, but as a strategy. We unpack inhibition modes (competitive, noncompetitive, mixed, uncompetitive), the messy truth of CYP450 allostery and DDIs, and why allosteric control can protect potency in substrate-rich environments. Plus: a mindset masterclass from Dr. Eric Trinquet —how structured play turns into assays and why serendipity belongs in your build process. And a tertiary read on ciliary micro-domains linking OPN3/MCR signaling to appetite and skin biology. Read the full Weekly News ➤ https://lnkd.in/eWkAphen If this helped, pass it along to a colleague who needs the signal. #DrGPCR #GPCR Recent Articles Previous Next

Home → Flash News → What do you want to learn today? If you’re an Ecosystem Member, you can learn something new every day! 🚀 Take one of our courses On-Demand and expand your knowledge of GPCRs. ✳️Discover your next learning experience at https://www.ecosystem.drgpcr.com/gpcr-courses #gpcr #drgpcr Published on February 13, 2025 Category Dr. GPCR Courses What do you want to learn today? If you’re an Ecosystem Member, you can learn something new every day! 🚀 Take one of our courses On-Demand and expand your knowledge of GPCRs. ✳️Discover your next learning experience at https://www.ecosystem.drgpcr.com/gpcr-courses #gpcr #drgpcr Recent Articles Previous Next

Home → Flash News → Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Published on May 22, 2025 Category Dr. GPCR Podcast Ben Clements reveals a 10x improvement in efficacy using GPCR-targeted PAMs, in Ep.166 of the Dr.GPCR Podcast,. The catch? It’s all about understanding the system, not replacing it. From neuromas to novel modulators, this episode is full of breakthroughs that matter for patients. 📲 Watch now: Ep 166 with Dr. Ben Clements #GPCRresearch #DrGPCR #GPCRpodcast #OpioidPharmacology #DrugDiscovery Recent Articles Previous Next

Home → Flash News → The Dr. GPCR Podcast is back! After a long break, a new episode will be released today 🎧 Join us in 2025 with a year filled with GPCRs, as we share with specialists about their career paths, the latest breakthroughs, their advice, and inspiring stories. 📅 Ep. 157 drops today January 9th at 10 AM EST. Don’t miss it! ✅ Stay tuned & subscribe at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-157-with-dr.-nagarajan-vaidehi Published on January 9, 2025 Category Dr. GPCR Podcast The Dr. GPCR Podcast is back! After a long break, a new episode will be released today 🎧 Join us in 2025 with a year filled with GPCRs, as we share with specialists about their career paths, the latest breakthroughs, their advice, and inspiring stories. 📅 Ep. 157 drops today January 9th at 10 AM EST. Don’t miss it! ✅ Stay tuned & subscribe at https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/ep-157-with-dr.-nagarajan-vaidehi Recent Articles Previous Next

Home → Flash News → Adenosine A3 receptor has been proposed to have significant roles in metabolism and immune responses. Check out this study to understand how it affects metabolic dysfunction-associated steatotic liver progression. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://buff.ly/42b6ra3 #gpcr #drgpcr Published on January 16, 2025 Category GPCR Weekly News Adenosine A3 receptor has been proposed to have significant roles in metabolism and immune responses. Check out this study to understand how it affects metabolic dysfunction-associated steatotic liver progression. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/a3ar-antagonism-mitigates-metabolic-dysfunction-associated-steatotic-liver-disease-by-exploiting-monocyte-derived-kupffer-cell-necroptosis-and-inflammation-resolution #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next

Home → Flash News → Seeking to gain more knowledge on signaling bias? We’ve got the perfect opportunity for you 🚀 Registrations open until February 14th ⚠️ Last spots available for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin ✳️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 8, 2025 Category Dr. GPCR Courses Seeking to gain more knowledge on signaling bias? We’ve got the perfect opportunity for you 🚀 Registrations open until February 14th ⚠️ Last spots available for “The Practical Assessment of Signaling Bias” with Dr. Terry Kenakin ✳️Register today at https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next

Home → Flash News → master gpcr pharmacologic models before its too late Published on July 11, 2025 Category GPCR Weekly News Most GPCR teams aren’t failing because of bad science. They’re stalling because of slow decisions, misapplied models, and buried priorities. This week’s GPCR Weekly News helps you fix that. Terry’s Corner breaks down the 4 pharmacologic models that separate forecasting from guessing. Dr. Sokhom S. Pin shares how he built high-output, low-burnout teams—and earned his PhD while working full time. Yamina’s Corner exposes the silent drift killing GPCR programs (and how to reverse it). 💡Plus: New tools from Celtarys Research . Biotech strategy moves from Catalio Capital Management . And your voice in our survey. If your competitors are already applying these insights… can you afford to skip this week’s update? ✳️ Read the Weekly News → https://www.ecosystem.drgpcr.com/post/crush-data-confusion-conquer-gpcr-drug-discovery?utm_content=bufferd9b30&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer #GPCR #Pharmacology #DrugDiscovery #ScientificLeadership #DrGPCR Recent Articles Beyond Clearance: The Strategic Power of Irreversible Drug Binding This session unpacks how persistent binding can either accelerate your program—or quietly kill it. That’s the power (and the peril) of irreversible drugs. These aren’t just “stronger binders.” They’re kinetic game-changers—compounds that rewrite the relationship between ligand, receptor, and physiologic outcome. Understanding how persistent binding affects receptor turnover, tissue penetration, and PK/PD relationships can give your team a strategic edge. 11 hours ago How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs Discover how Dr. Eric Trinquet, creator of HTRF and IP-One assays, turned failure into breakthrough tools for GPCR science. Learn why play, serendipity, and partnerships fuel innovation—and how this mindset can transform your research and biotech career. 5 days ago Understanding Enzyme Inhibition In GPCR Discovery Programs Every drug you design will meet an enzyme before it meets its receptor. If you want your molecules to survive first contact with biology—and with the FDA—enzyme inhibition must be part of your core playbook. This week’s feature breaks down exactly how to think about inhibitors with rigor and speed, so you can make better decisions earlier in the pipeline. Breakthroughs this week: Potentiation of GPCR signaling by ATP and sugar monophosphates; Pharmacology 2025; Nxera Pharma 5 days ago Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery Before your GPCR ligand ever meets its receptor, it meets the enzymes that determine whether it survives long enough to act. Recognizing, predicting, and leveraging these interactions is the essence of enzyme inhibition pharmacology—the framework that connects molecular survival to clinical success. Oct 14 Assay Volume Control: Your GPCR Drug Discovery Power Lever If you want cleaner decisions, start with the system—then the ligand. This week’s lead feature unlocks a deceptively simple lever that separates signal from storytelling, moving programs forward with fewer surprises. That’s precisely what Terry’s Corner delivers: practical tools from Dr. Terry Kenakin to elevate your science and sharpe It’s a curated toolkit designed to help GPCR professionals move faster, with more confidence. Premium Members count on this every week—and t Oct 9 Previous Next

Awkward... This page isn’t available. Go Home

Home → Flash News → Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox Unlocking the activation process of PTH1R: New computational insights into its molecular interactions bring us closer to better osteoporosis treatments! ➡️https://www.ecosystem.drgpcr.com/receptor-activation-and-signaling/key-interaction-changes-determine-the-activation-process-of-human-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Published on February 6, 2025 Category GPCR Weekly News Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox Unlocking the activation process of PTH1R: New computational insights into its molecular interactions bring us closer to better osteoporosis treatments! ➡️ https:// www.ecosystem.drgpcr.com/receptor-activation-and-signaling/key-interaction-changes-determine-the-activation-process-of-human-parathyroid-hormone-type-1-receptor #gpcr #drgpcr Recent Articles Previous Next

Home → Flash News → Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Published on June 3, 2025 Category Dr. GPCR Podcast Autoantibodies that activate GPCRs? Wild—but real. Tom Sakmar & Ilana Kotliar break down the link between GPCR autoantibodies, long COVID, and disease signaling in Ep.167 of the Dr.GPCR Podcast This episode is a must if you're thinking diagnostics. 📲 Tap to listen: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRautoantibodies #GPCRdrugdiscovery #DrGPCR #Immunology Recent Articles Previous Next

Home → Flash News → "Solving financial puzzles feels just like solving scientific ones," says Joe St. Germain from Company Launch Partners. Behind every successful research organization, there is a rock-solid operations team. Don’t miss this rare conversation bridging science, structure, and strategy with Chuck DeWeese & Joe St. Germain. ✳️ Tune in now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Published on May 1, 2025 Category Dr. GPCR Podcast "Solving financial puzzles feels just like solving scientific ones," says Joe St. Germain from Company Launch Partners.Behind every successful research organization, there is a rock-solid operations team. Don’t miss this rare conversation bridging science, structure, and strategy with Chuck DeWeese & Joe St. Germain. ✳️ Tune in now: Ep 165 with Chuck DeWeese & Joe St. Germain #gpcr #DrGPCR #ScienceStartup Recent Articles Previous Next